Table 1.
Laboratory data on admission
| RBC | 265 × 104/mm3 | ALP | 423 IU/l | Anti-HBs (−) 0.1 mlU/ml | |
| Hb | 8.5 g/dl | LDH | 825 IU/l | ||
| Hct | 25.8% | γ-GTP | 92 IU/l | HBeAg (−) 0.1-fold | |
| WBC | 1,500/mm3 | Total bilirubin | 0.5 mg/dl | Anti-HBe (+) 100% | |
| Band | 17% | BUN | 12.2 mg/dl | ||
| Seg | 35% | Cr | 0.69 mg/dl | ||
| Eo | 0% | UA | 3.7 mg/dl | Anti-HBc (2+) 80.8% | |
| Baso | 2% | T.P | 6.1 g/dl | ||
| Mono | 25% | Alb | 63.4% | Anti-HBc lgM (−) C·O.I 0.11 | |
| Lympho | 18% | α1-gl | 4.8% | ||
| At.lym | 3% | α2-gl | 10.9% | HBV DNA 7.5 log copies/ml | |
| Plt | 14.8 × 104/mm3 | β−gl | 8.5% | HBV genotype Bj | |
| γ-gl | 12.4% | HBV precore mutation wild:mutant = 40:60 | |||
| CRP | 2.26 mg/dl | TC | 161 mg/dl | HBV core promoter wild type | |
| TG | 91 mg/dl | ||||
| AST | 1,491 IU/l | PT | 69% | Anti-HCV (−) | |
| ALT | 1,113 IU/l | HBsAg | (+) 2,000 U/ml | Anti-HAlgM (−) | |
RBC; red blood cell counts; Hb, hemoglobin; Hct, hematocrit; WBC, white blood cell counts; Band, Band neutrophils; Seg, segmented neutrophils; Eo, eosinophils; Baso, basophils; Mono, monocytes; Lympho, lymphocytes; At.lym, atypical lymphocytes; Plt, platelet counts; CRP, C-reactive protein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; LDH, lactate dehydrogenase; γ-GTP, gamma-glutamyl transpeptidase; BUN, blood urea nitrogen; Cr, creatinine; UA, uric acid; T.P., total protein; Alb, albumin; α1-gl, α1-globulin; α2-gl, α2-globulin; β-gl, β-globulin; γ-gl, γ-globulin; TC, total cholesterol; TG, triglyceride; PT, prothrombin time